Duligotumab

Duligotuzumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	HER3
Clinical data
ATC code	none;
Identifiers
CAS Number	1314238-96-4;
ChemSpider	none;
UNII	8PMF8YQX2T;
KEGG	D11750;

Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3.^[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.^[2]

References

^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
^ "Duligotuzumab". AdisInsight.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Duligotumab
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[2] "Duligotuzumab". AdisInsight.

[1]

[2]